Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $100.86 -0.91%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.4 million.
Halozyme Therapeutics sees FY2015 revenue of $85-95 million, versus the consensus of $93.3 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance
- StoneCo (STNE) Reports In-Line Q2 EPS
- Caribou Biosciences, Inc. (CRBU) Tops Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
